Jens Kjeldsen-Kragh
Overview
Explore the profile of Jens Kjeldsen-Kragh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geisen C, Fleck E, Schafer S, Walter C, Braeuninger S, Jensen J, et al.
Thromb Haemost
. 2024 Aug;
PMID: 39168139
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare bleeding disorder of the fetus/newborn caused by development of maternal alloantibodies against fetal human platelet antigens (HPAs), predominantly HPA-1a. Currently...
2.
Bjurstrom M, Linder Y, Kjeldsen-Kragh J, Bengtsson J, Kander T
Acta Anaesthesiol Scand
. 2024 Mar;
68(6):812-820.
PMID: 38453453
Background: Randomized controlled trials relatively consistently show that restrictive red blood cell (RBC) transfusion strategies are safe and associated with similar outcomes compared to liberal transfusion strategies in critically ill...
3.
Kjeldsen-Kragh J, Bein G, Tiller H
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685558
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition in which maternal alloantibodies to fetal platelets cause fetal thrombocytopenia that may lead to intracranial hemorrhage (ICH). Off-label intravenous immunoglobulin...
4.
Ernstsen S, Kjeldsen-Kragh J, Tiller H
Am J Obstet Gynecol
. 2023 Feb;
228(6):760-761.
PMID: 36736678
No abstract available.
5.
Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, et al.
J Thromb Haemost
. 2023 Jan;
21(4):838-849.
PMID: 36696185
Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associated with the most frequent FNAIT...
6.
Kjeldsen-Kragh J, Hellberg A
J Clin Med
. 2022 May;
11(10).
PMID: 35629001
Hemolytic disease of the fetus and newborn (HDFN), as well as fetal and neonatal alloimmune thrombocytopenia (FNAIT), represent two important disease entities that are caused by maternal IgG antibodies directed...
7.
Ernstsen S, Ahlen M, Johansen T, Bertelsen E, Kjeldsen-Kragh J, Tiller H
Am J Obstet Gynecol
. 2022 May;
227(3):506.e1-506.e12.
PMID: 35500612
Background: Maternal alloantibodies to human platelet antigen-1a can cause severe intracranial hemorrhage in a fetus or newborn. Although never evaluated in placebo-controlled clinical trials, most Western countries use off-label weekly...
8.
Ljungquist O, Lundgren M, Iliachenko E, Mansson F, Bottiger B, Landin-Olsson M, et al.
Infect Dis (Lond)
. 2021 Dec;
54(4):283-291.
PMID: 34878955
Background: Immunosuppressed patients are particularly vulnerable to severe infection from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), risking prolonged viremia and symptom duration. In this study we describe clinical...
9.
Holm K, Lundgren M, Kjeldsen-Kragh J, Ljungquist O, Bottiger B, Wiken C, et al.
BMC Res Notes
. 2021 Dec;
14(1):440.
PMID: 34863304
Objective: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were...
10.
Axfors C, Janiaud P, Schmitt A, Vant Hooft J, Smith E, Haber N, et al.
BMC Infect Dis
. 2021 Nov;
21(1):1170.
PMID: 34800996
Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of...